KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to 0.15%.

  • Alnylam Pharmaceuticals' Return on Capital Employed rose 2000.0% to 0.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.15%, marking a year-over-year increase of 2000.0%. This contributed to the annual value of 0.16% for FY2025, which is 2200.0% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.15% for Q4 2025, which was up 2000.0% from 0.08% recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.15% for Q4 2025, and its period low was 0.32% during Q2 2023.
  • For the 5-year period, Alnylam Pharmaceuticals' Return on Capital Employed averaged around 0.15%, with its median value being 0.18% (2022).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Return on Capital Employed soared by 3500bps in 2024 and then tumbled by -900bps in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.25% in 2021, then dropped by -14bps to 0.28% in 2022, then skyrocketed by 65bps to 0.1% in 2023, then skyrocketed by 41bps to 0.06% in 2024, then soared by 350bps to 0.15% in 2025.
  • Its Return on Capital Employed was 0.15% in Q4 2025, compared to 0.08% in Q3 2025 and 0.06% in Q2 2025.